Results 51 to 60 of about 39,211 (299)
Classical twin design in modern pharmacogenomics studies.
, 2020 Response to medication is highly variable, unpredictable and, at times, may be fatal. All drugs are more effective in certain groups of the population while showing no or minimal benefit in other groups.
Rahmioğlu, N, Ahmadi, KR
core +1 more source
AI‐Driven Cancer Multi‐Omics: A Review From the Data Pipeline Perspective
Advanced Intelligent Discovery, EarlyView.The exponential growth of cancer multi‐omics data brings opportunities and challenges for precision oncology. This review systematically examines AI's role in addressing these challenges, covering generative models, integration architectures, Explainable AI for clinical trust, clinical applications, and key directions for clinical translation.
Shilong Liu, Shunxiang Li, Kun Qian
wiley +1 more source
Clinical and Translational ScienceLack of pharmacogenomics knowledge among healthcare professionals is the most significant cited barrier to implementing pharmacogenomics in clinical settings.
Safa Omran +5 more
doaj +1 more source
Frontiers in Pharmacology, 2014 The development of clinical practice recommendations or guidelines for the clinical use of pharmacogenomics data is an essential issue for improving drug therapy, particularly for drugs with high toxicity and/or narrow therapeutic index such as ...
José A G Agúndez +7 more
doaj +1 more source
Molecular Functions of WWOX Potentially Involved in Cancer Development
Cells, 2021 The WW domain-containing oxidoreductase gene (WWOX) was cloned 21 years ago as a putative tumor suppressor gene mapping to chromosomal fragile site FRA16D. The localization of WWOX in a chromosomal region frequently altered in human cancers has initiated
Karim Taouis +3 more
doaj +1 more source
American Journal of Medical Genetics Part A, EarlyView.ABSTRACT Genetic modifiers of Duchenne muscular dystrophy (DMD) that alter disease severity or response to therapy have been reported using natural history or registry data sets of older corticosteroid‐treated patients. We tested associations of genetic modifiers on motor function outcomes in young (4 to < 7 years) steroid naïve clinical trial ...
Utkarsh J. Dang +16 more
wiley +1 more source
Implementing health economics for pharmacogenomics research translation in Africa
Communications MedicinePharmacogenomics studies how a person’s inherited genes influence response to therapeutic drugs. Many drugs do not work in all patients and pharmacogenomics can assist in the identification of patients who are better suited to particular drugs or ...
Mohamed Zahir Alimohamed +4 more
doaj +1 more source
Risk Management and Healthcare Policy, 2020 Mohammed Algahtani Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Kingdom of Saudi ArabiaCorrespondence: Mohammed Algahtani Email msalqahtane@nu.edu.saIntroduction: The accelerated transformation in the healthcare system ...
Algahtani M
doaj
Pharmacogenomics perspective for forensic toxicology: A mini review
Medicine Science, 2022 Pharmacogenetic and Pharmacogenomics are the study of the association between an individual's genotype and their response to xenobiotics Pharmacokinetic and pharmacodynamics variations can appear at the level of drug-metabolizing enzymes, drug ...
Dilek Battal +3 more
doaj +1 more source
Delayed Recognition of Maternal G6PD Heterozygous Status Across Prenatal and Newborn Care Interfaces
American Journal of Medical Genetics Part A, EarlyView.ABSTRACT Glucose‐6‐phosphate dehydrogenase (G6PD) deficiency is the most common red blood cell enzymatic disorder worldwide. Although many heterozygotes are asymptomatic, affected neonates have an increased risk for hyperbilirubinemia and related complications.
Mona M. Makhamreh +5 more
wiley +1 more source